Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest Income - NetInterest Income - TotalNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax Provisions
Others
Ratios

Abeona Therapeutics (ABEO) Profit After Tax: 2011-2025

Historic Profit After Tax for Abeona Therapeutics (ABEO) over the last 14 years, with Sep 2025 value amounting to -$5.2 million.

  • Abeona Therapeutics' Profit After Tax rose 82.95% to -$5.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $82.3 million, marking a year-over-year increase of 215.93%. This contributed to the annual value of -$63.7 million for FY2024, which is 17.62% down from last year.
  • Per Abeona Therapeutics' latest filing, its Profit After Tax stood at -$5.2 million for Q3 2025, which was down 104.74% from $108.8 million recorded in Q2 2025.
  • Over the past 5 years, Abeona Therapeutics' Profit After Tax peaked at $108.8 million during Q2 2025, and registered a low of -$46.7 million during Q4 2021.
  • Over the past 3 years, Abeona Therapeutics' median Profit After Tax value was -$11.8 million (recorded in 2023), while the average stood at -$2.4 million.
  • Its Profit After Tax has fluctuated over the past 5 years, first crashed by 306.49% in 2023, then spiked by 1,369.52% in 2025.
  • Quarterly analysis of 5 years shows Abeona Therapeutics' Profit After Tax stood at -$46.7 million in 2021, then soared by 84.75% to -$7.1 million in 2022, then crashed by 132.99% to -$16.6 million in 2023, then surged by 43.99% to -$9.3 million in 2024, then soared by 82.95% to -$5.2 million in 2025.
  • Its last three reported values are -$5.2 million in Q3 2025, $108.8 million for Q2 2025, and -$12.0 million during Q1 2025.